Craniofacial Abnormalities
Methodology & AI Transparency ⓘ
Craniofacial Abnormalities Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Craniofacial is a medical term that relates to the bones of the skull and face.
- 2 Real-world patient consensus: Clinical coding for Craniofacial Abnormalities uses ICD-10 M19.0 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Primary evaluation for Craniofacial Abnormalities incorporates synovial fluid crystal/cell in Craniofacial Abnormalities (M19.0: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Craniofacial Abnormalities: maintaining hs-CRP & Erythrocyte in Craniofacial Abnormalities (M19.0: Sedimentation Rate) within hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M19.0).
Ask our AI Specialists anything about Craniofacial Abnormalities
What Is Craniofacial Abnormalities?
Craniofacial is a medical term that relates to the bones of the skull and face. Craniofacial abnormalities are birth defects of the face or head. Some, like cleft lip and palate , are among the most common of all birth defects. Others are very rare. Most of them affect how a person's face or head looks. These conditions may also affect other parts of the body. Treatment depends on the type of problem. Plastic and reconstructive surgery may help the person's appearance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Craniofacial Abnormalities (code M19.0) is monosodium urate or in Craniofacial Abnormalities (M19.0: calcium pyrophosphate crystal), Cross-referenced with NIH MeSH (Craniofacial Abnormalities), which Osteoarthritis, Gout & Joint Pain clinicians address while surveilling hs-CRP & Erythrocyte in Craniofacial Abnormalities (M19.0: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M19.0)).
Common Symptoms & Clinical Signs
- • Presentation of Craniofacial Abnormalities (M19.0): localized tendon or in Craniofacial Abnormalities (M19.0: bursa tenderness limiting)
- • Secondary Craniofacial Abnormalities clinical sign: activity-related deep aching in Craniofacial Abnormalities (M19.0: joint pain in)
- • Symptom flares in Craniofacial Abnormalities correlating with hs-CRP & Erythrocyte in Craniofacial Abnormalities (M19.0: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M19.0)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Craniofacial Abnormalities (M19.0: analysis when effused) evaluation (M19.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Craniofacial Abnormalities Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M19.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Craniofacial Abnormalities (M19.0: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M19.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Craniofacial Abnormalities M19.0] | Preserved joint-space width (M19.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Craniofacial Abnormalities (M19.0: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M19.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Craniofacial Abnormalities
Treatment selection for Craniofacial Abnormalities depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Craniofacial Abnormalities)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Custom Non-invasive Ventilation Masks in While the technology has improved with development of masks specifically for children, the range of options remains limited. ClinicalTrials.gov Registry (NIH NLM) • 2026-07-27 • Completed Human Clinical Trial (NCT) | N = 16 | 89/100 | PMID NCT05336136 ↗ |
| New Insights on Benefits and safety of secukinumab in patients with spondyloarthritis and: What a 204-Participant Study Found A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging... Rheumatology (Oxford, England) • 2022-07-06 • Phase III Randomized Trial | N = 204 | 88/100 | PMID 34730795 ↗ |
| Can This Approach Help? Inside the Latest Research on Serum uric acid level in male patients with androgenetic hair loss: A prospective We found that AGA has a relationship with hyperuricemia, and the level of serum UA can decrease with the treatment of finasteride. The American journal of the medical sciences • 2023-11-15 • Randomized Controlled Trial | N = 60 | 88/100 | PMID 37553022 ↗ |
| What the Latest Evidence Really Says About Craniofacial and upper airway morphology in adult obstructive sleep apnea There is a strong evidence for reduced pharyngeal airway space, inferiorly placed hyoid bone and increased anterior facial heights in adult OSA patients compared to control subjects. Sleep medicine reviews • 2017-02-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 27039222 ↗ |
| Can This Approach Help? Inside the Latest Research on Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in OZR is an effective anti-TNF treatment for RA, regardless of RF and ACPA titres, and exhibits promise as a novel therapeutic option. Rheumatology (Oxford, England) • 2025-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40139716 ↗ |
Craniofacial Abnormalities Patient Community & “People Like Me” Threads
Filter Craniofacial Abnormalities community threads and patient logs by age, biological sex, dosage, and treatment duration.